New Opportunities for Targeting the Androgen Receptor in Prostate Cancer
- Margaret M. Centenera1,2,
- Luke A. Selth1,3,
- Esmaeil Ebrahimie3,
- Lisa M. Butler1,2 and
- Wayne D. Tilley1,3
- 1Adelaide Medical School and Freemasons Foundation Centre for Men’s Health, University of Adelaide, Adelaide SA 5005, Australia
- 2South Australian Health and Medical Research Institute, Adelaide SA 5001, Australia
- 3Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, Adelaide SA 5005, Australia
- Correspondence: wayne.tilley{at}adelaide.edu.au
Abstract
Recent genomic analyses of metastatic prostate cancer have provided important insight into adaptive changes in androgen receptor (AR) signaling that underpin resistance to androgen deprivation therapies. Novel strategies are required to circumvent these AR-mediated resistance mechanisms and thereby improve prostate cancer survival. In this review, we present a summary of AR structure and function and discuss mechanisms of AR-mediated therapy resistance that represent important areas of focus for the development of new therapies.
